Simplifying Software Security: Veracode Enhances Frictionless Experience for Developers
14.9.2022 21:33:00 EEST | Business Wire | Press release
Black Hat (booth #2428) – Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform with substantial improvements to its integrated developer experience. New features include extended integrations to support software composition analysis (SCA), a software bill of materials (SBOM) Application Programming Interface (API), and additional language and framework support for static analysis, further enhancing developers’ ability to secure software in the environments where they work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005141/en/
Fig. 1 Veracode “Beat the Heat” security flaw heat map, State of Software Security Report v12 (Graphic: Business Wire)
Brian Roche, Chief Product Officer at Veracode, said, “Modern applications are mostly assembled, not written from scratch. Open-source code makes up a significant proportion of audited code bases—for example, 97 percent of the typical Java application is made up of open-source libraries*—increasing security risk and the need to identify supply chain risk. Our SBOM API, is designed to make it easier for developers to inventory their code base, including third-party components, allowing them to act quickly if new vulnerabilities emerge. Since the launch of our Continuous Software Security Platform in May, we have introduced additional capabilities that meet developers right where they work: in the integrated developer environment (IDE), code repository, and command line interface. These innovations are designed to drive adoption by making the platform even more developer friendly.”
Facilitating DevSecOps
Veracode’s platform supports 100+ languages and frameworks, including those for cloud-native application development and older languages used with legacy assets, like COBOL. Large enterprises have applications across myriad languages and being able to deploy a continuous security testing solution across them simplifies the process, while providing consistent results. The company’s latest State of Software Security (SoSS) 12 research analyzed the most common flaws by language and revealed that a prevalent flaw for one language may not be of any concern for another. For example, cross-site scripting (XSS) is the most common flaw for PHP, at 77 percent, but doesn’t even make the top 10 for C++*. Moreover, flaws change constantly, meaning that even if a flaw isn’t prevalent in a programming language, practitioners should still take active steps to prevent it from impacting their code. Since remediation tactics vary by flaw and programming language, having a broad array of language support in one place makes developers’ jobs easier by freeing up their time to focus on meeting tight deployment deadlines.
Frequent scanning of first- and third-party code mitigates the risk from both proprietary and open-source vulnerabilities, such as Log4j. Veracode’s new developer-centric tools and services are designed to make this a quicker and easier process, particularly with the additional capability of third-party proprietary library scanning.
Peter Evans, Engineering Director at QAD Precision GTTE, said, “Veracode brought a complete platform for us to build security tools into our development pipelines, as well as helped us grow our knowledge to keep getting better at security. Veracode was also a good fit because the platform can scan Java code in the Spring framework where we develop our software. We’ve gone from reviewing code to integrating continuous scans into our daily pipelines. Security threats don’t stand still and Veracode provides us the tools to keep up with the latest vulnerabilities and rules.”
Notable updates to the Veracode Continuous Software Security platform include:
SBOM for SCA
- With government regulations driving standards for securing software supply chains, having an SBOM is increasingly important for organizations. Veracode’s SBOM API in SCA enables developers to easily generate an SBOM in CycloneDX JSON format—one of the approved formats for compliance with the U.S. Executive Order. This helps confirm the code they’re using, or building, is free from vulnerabilities.
IDE and Integrations for SCA
To make software security a seamless experience, Veracode continues to introduce integrations that meet developers where they work.
- The Veracode Azure DevOps Extension has a new “SCA Flaw Importer” to automatically import SCA flaws into Azure DevOps Boards and Work Items
- The soon-to-be-released Veracode for Visual Studio Code extension provides detailed information on vulnerabilities, licence risks, and recommended versions of open-source libraries and transitive dependencies so developers can rapidly respond to any risks
Expanded Frameworks and Languages Support for Static Analysis
- The company is committed to keeping up with the latest language and frameworks with which developers work, adding support for Rails 7.0, Ruby 3.x, and PHP Symfony
Roche concluded, “As a pioneer of application security, we are uniquely positioned to combine unrivalled experience with the latest innovations in cloud development. Unlike on-premise vendors, our SaaS solution is both scalable and elastic, meaning customers are always prepared to meet unexpected demand. Powered by nearly two decades of cumulative data, our platform provides detailed comparative historical reviews against industry benchmarks and peers—a level of insight highly relevant for leadership teams and the board. Our platform also saves developers time by delivering highly accurate results and enabling them to find and fix vulnerabilities in minutes, meaning they can ship code quickly with the confidence that it is secure.”
Developers can learn more about Veracode’s platform, the frictionless developer experience, and how to simply and maturely secure their SDLC by visiting Veracode’s booth #2428 at Black Hat USA.
*Veracode State of Software Security Report v12, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005141/en/
Contact information
Press and Media
Katy Gwilliam
Head of Global PR, Veracode
kgwilliam@veracode.com
+44.7584.341.110
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
